- Durham, NC-based Viamet Pharmaceuticals Holdings (VMET) is set for its IPO of 5.7M shares of common stock at $14 - 16.
- The biopharmaceutical firm develops drugs based on its proprietary metalloenzyme chemistry and biology technology platform called MIDAS. Metalloenzymes, a key class of drug targets for a broad range of diseases, contain a metallic atom that is primarily responsible for enzyme activity. Its lead product candidate is Phase 2b-stage VT-1161 for the treatment of onychomycosis, a fungal infection of the nail and recurrent vulvovaginal candidiasis, a recurrent form of vaginal yeast infection. Top-line data from the Phase 2b study should be available in Q4. Other pipeline candidates include Phase 1-stage VT-1129 for the treatment of cryptococcal meningitis and IND-stage VT-1598 for the treatment of coccidiodomycosis, a fungal infection in the southwestern U.S. known as Valley Fever.
- 2015 Financials ($M): Revenue: 0.7 (+242.9%); Operating Expenses: 30.1 (+87.2%); Net Loss: (39.3) (-71.7%); Cash Burn: (26.7) (-45.7%).